Session Information

  • WCLC 2020

    2020 World Conference on Lung Cancer

    Conference Program for the 2020 World Conference on Lung Cancer in Singapore


    Presentation Date(s):  
    • January 28 - 31, 2021
    • Total Presentations: 1597

    All times listed are in Singapore time (GMT+8)

    PL - Plenary
    PS - Presidential Symposium
    ES - Education Session
    OA - Oral Session
    MA - Mini Oral Session
    FP - Featured Posters
    P - Posters
    IS - Industry Symposium
    JICC - Joint IASLC-CAALC-CSCO Session

Filter Results:

Show Only CME Accredited Sessions

  • +

    FP03 - Immuno-biology and Novel Immunotherapeutics (Phase I and Translational)

    • 00:00 - 00:00
    • 1/28/2021
    • Location: ePoster Hall
    • Type: Posters (Featured)
    • Track: Immuno-biology and Novel Immunotherapeutics (Phase I and Translational)
    • +

      FP03.02 - Interim Analysis of Neoadjuvant Chemoradiotherapy and Durvalumab for Potentially Resectable Stage III Non-Small Cell Lung Cancer (NSCLC)

      00:00 - 00:00  |  Presenter: Min Hee Hong

      • Abstract

      Loading...

  • +

    FP13 - Immunotherapy (Phase II/III Trials)

    • 00:00 - 00:00
    • 1/28/2021
    • Location: ePoster Hall
    • Type: Posters (Featured)
    • Track: Immunotherapy (Phase II/III Trials)
    • +

      FP13.01 - 5-Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel in Previously Treated, PD-L1–Positive Advanced NSCLC

      00:00 - 00:00  |  Presenter: Roy S. Herbst

      • Abstract

      Loading...

    • +

      FP13.04 - KEYNOTE-042 3-Year Survival Update: 1L Pembrolizumab vs Platinum-Based Chemotherapy for PD-L1+ Locally Advanced/Metastatic NSCLC

      00:00 - 00:00  |  Presenter: Byoung Chul Cho

      • Abstract

      Loading...

  • +

    FP14 - Targeted Therapy - Clinically Focused

    • 00:00 - 00:00
    • 1/28/2021
    • Location: ePoster Hall
    • Type: Posters (Featured)
    • Track: Targeted Therapy - Clinically Focused
    • +

      FP14.03 - Osimertinib + Savolitinib in pts with EGFRm MET-Amplified/Overexpressed NSCLC: Phase Ib TATTON Parts B and D Final Analysis

      00:00 - 00:00  |  Presenter: Ji-Youn Han

      • Abstract

      Loading...

    • +

      FP14.10 - Efficacy and Safety of Selpercatinib (LOXO-292) in East Asian Patients with RET Fusion-Positive NSCLC

      00:00 - 00:00  |  Presenter: Herbert H Loong

      • Abstract

      Loading...

    • +

      FP14.14 - Post Hoc Analyses from an Open Label, Multi-Centre, ASTRIS Trial of Efficacy of Osimertinib for CNS Metastases with T790M-Positive Advanced NSCLC

      00:00 - 00:00  |  Presenter: Beung-Chul Ahn

      • Abstract

      Loading...

  • +

    P04 - Early Stage/Localized Disease - Perioperative Therapy (Neoadjuvant Therapy, Surgery, Adjuvant Therapy)

    • 00:00 - 00:00
    • 1/28/2021
    • Location: ePoster Hall
    • Not for CME Credit
    • Type: Posters
    • Track: Early Stage/Localized Disease
    • +

      P04.03 - Patient Characteristics and Clinical Outcomes of Stage III NSCLC in a Real-World Setting: KINDLE Korean Subset Data.

      00:00 - 00:00  |  Presenter: Byoung Chul Cho

      • Abstract

      Loading...

  • +

    P76 - Targeted Therapy - Clinically Focused - EGFR

    • 00:00 - 00:00
    • 1/28/2021
    • Location: ePoster Hall
    • Not for CME Credit
    • Type: Posters
    • Track: Targeted Therapy - Clinically Focused
    • +

      P76.18 - Tissue- and Plasma-Based Landscape of Resistance to Osimertinib

      00:00 - 00:00  |  Presenter: Sun Min Lim

      • Abstract

      Loading...

    • +

      P76.27 - ORCHARD: A Biomarker-Directed Phase 2 Platform Study in pts with Advanced EGFRm NSCLC Progressing on First-Line Osimertinib

      00:00 - 00:00  |  Presenter: Byoung Chul Cho

      • Abstract

      Loading...

  • +

    P77 - Immunotherapy (Phase II/III Trials) - Combining Different Immunotherapeutic Approaches

    • 00:00 - 00:00
    • 1/28/2021
    • Location: ePoster Hall
    • Not for CME Credit
    • Type: Posters
    • Track: Immunotherapy (Phase II/III Trials)
    • +

      P77.02 - Efficacy of Tiragolumab + Atezolizumab in PD-L1 IHC and TIGIT Subgroups in the Phase II CITYSCAPE Study in First-Line NSCLC

      00:00 - 00:00  |  Presenter: Byoung Chul Cho

      • Abstract

      Loading...

  • +

    P84 - Targeted Therapy - Clinically Focused - ALK

    • 00:00 - 00:00
    • 1/28/2021
    • Location: ePoster Hall
    • Not for CME Credit
    • Type: Posters
    • Track: Targeted Therapy - Clinically Focused
    • +

      P84.05 - Efficacy and Safety of Ceritinib 450-mg Fed vs 750-mg Fasted in Patients with ALK+ NSCLC: Final Report of the ASCEND-8 Trial

      00:00 - 00:00  |  Presenter: Byoung Chul Cho

      • Abstract

      Loading...

  • +

    P86 - Targeted Therapy - Clinically Focused - New Target

    • 00:00 - 00:00
    • 1/28/2021
    • Location: ePoster Hall
    • Not for CME Credit
    • Type: Posters
    • Track: Targeted Therapy - Clinically Focused
    • +

      P86.12 - Cardiac Safety Assessment of Lazertinib in Patients with EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer

      00:00 - 00:00  |  Presenter: Nahor Haddish-Berhane

      • Abstract

      Loading...

  • +

    P89 - Targeted Therapy - Clinically Focused - Translational

    • 00:00 - 00:00
    • 1/28/2021
    • Location: ePoster Hall
    • Not for CME Credit
    • Type: Posters
    • Track: Targeted Therapy - Clinically Focused
    • +

      P89.08 - Real-World Impact of Plasma Cell-Free DNA Next-Generation Sequencing to Detect Actionable Genomic Alterations in Advanced NSCLC

      00:00 - 00:00  |  Presenter: Beung-Chul Ahn

      • Abstract

      Loading...

  • +

    OA04 - New Data from Rare EGFR Alterations

    • 11:45 - 12:45
    • 1/29/2021
    • Location: Scientific Program Auditorium
    • IASLC CME Accredited
    • Type: Oral
    • Track: Targeted Therapy - Clinically Focused
    • +

      OA04.04 - Amivantamab in Post-platinum EGFR Exon 20 Insertion Mutant Non-small Cell Lung Cancer

      11:55 - 12:05  |  Presenter: Joshua K. Sabari

      • Abstract

      Loading...